Bradshaw Amy, Wickremsekera Agadha, Tan Swee T, Peng Lifeng, Davis Paul F, Itinteang Tinte
Gillies McIndoe Research Institute , Wellington , New Zealand.
Gillies McIndoe Research Institute, Wellington, New Zealand; Department of Neurosurgery, Wellington Regional Hospital, Wellington, New Zealand.
Front Surg. 2016 Apr 15;3:21. doi: 10.3389/fsurg.2016.00021. eCollection 2016.
Glioblastoma multiforme (GBM), an aggressive tumor that typically exhibits treatment failure with high mortality rates, is associated with the presence of cancer stem cells (CSCs) within the tumor. CSCs possess the ability for perpetual self-renewal and proliferation, producing downstream progenitor cells that drive tumor growth. Studies of many cancer types have identified CSCs using specific markers, but it is still unclear as to where in the stem cell hierarchy these markers fall. This is compounded further by the presence of multiple GBM and glioblastoma cancer stem cell subtypes, making investigation and establishment of a universal treatment difficult. This review examines the current knowledge on the CSC markers SALL4, OCT-4, SOX2, STAT3, NANOG, c-Myc, KLF4, CD133, CD44, nestin, and glial fibrillary acidic protein, specifically focusing on their use and validity in GBM research and how they may be utilized for investigations into GBM's cancer biology.
多形性胶质母细胞瘤(GBM)是一种侵袭性肿瘤,通常治疗失败且死亡率高,与肿瘤内癌症干细胞(CSC)的存在有关。癌症干细胞具有持续自我更新和增殖的能力,产生驱动肿瘤生长的下游祖细胞。许多癌症类型的研究已使用特定标志物鉴定出癌症干细胞,但这些标志物在干细胞层级结构中的位置仍不清楚。多种GBM和胶质母细胞瘤癌症干细胞亚型的存在使情况更加复杂,导致难以开展通用治疗的研究与确立。本综述探讨了关于癌症干细胞标志物SALL4、OCT-4、SOX2、STAT3、NANOG、c-Myc、KLF4、CD133、CD44、巢蛋白和胶质纤维酸性蛋白的现有知识,特别关注它们在GBM研究中的用途和有效性,以及如何将它们用于GBM癌症生物学的研究。